{"filings":[{"id":648523,"accession_number":"0001683168-26-004280","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2026-05-22T23:07:29+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends $1.05M convertible note maturity to Sept 30, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 12 with LGH Investments extends maturity of $1.05M convertible note to September 30, 2026.","All other terms and conditions of the original note remain unchanged.","Amendment effective April 30, 2026, entered into on May 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15243,"accession_number":"0001683168-26-003682","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2026-05-11T21:10:17+00:00","items":["1.01","9.01"],"status":"ready","headline":"Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.","NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.","Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.","Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94176,"accession_number":"0001683168-26-003205","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.","BreastCheck is a non-invasive, 15-minute test for breast abnormalities, registered with FDA, EU, and UK regulators.","Global breast cancer screening market estimated at $26B; commercial sales expected to begin in H2 2026.","CEO Michael Redmond says agreement provides clear pathway to near-term revenue and supports growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106364,"accession_number":"0001683168-26-000730","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity dates on convertible notes with insiders and LGH Investments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended notes with two directors and two officers (each $25,000) to mature Jan 31, 2027.","Amended $1,050,000 convertible note with LGH Investments to mature Apr 30, 2026.","Extended promissory note with accredited investor Jonathan Lutz to Jan 31, 2027.","Extended promissory note with accredited investor Peter J. D'Arruda to Jan 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122702,"accession_number":"0001683168-25-008530","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Odyssey Health secures up to $25M financing facility and 9-year service contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Maintenance Agreement with Mast Hill Fund; issued $2.262M convertible note at 10% interest due Nov 2026.","Securities Purchase Agreement provides up to $25M in multiple tranches; first tranche $500K with $437,500 net proceeds.","Initial $500K tranche directed to BreastCheck® sub-licensing program.","Service contract generates ~$245K/year recurring revenue through Feb 2034.","Convertible notes and warrants issuable at 85% of lowest VWAP over prior 10 trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122701,"accession_number":"0001683168-25-007644","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Odyssey Health signs exclusive worldwide sub-license for BreastCheck non-invasive breast test","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sub-license grants exclusive global marketing and distribution rights for BreastCheck, a 15-minute at-home test.","BreastCheck is FDA registered in the US and registered in EU and UK; targets $26B breast cancer diagnostics market.","Deal managed through subsidiary Odyssey Medical Devices; subject to closing conditions.","CEO expects near-term commercialization and initial revenue, marking transition from development-stage to revenue-generating.","No financial terms (upfront fee, milestones, royalties) disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122700,"accession_number":"0001683168-25-007502","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity of $870K promissory note to April 2026, removes amortization payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Enters Amendment No. 6 with Mast Hill Fund L.P. on $870,000 promissory note originally issued Dec 13, 2022.","Maturity date extended to April 30, 2026 from prior maturity (previously amended).","Amortization payment requirement (Section 4.16) deleted from the note.","All other terms and conditions of the note remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122699,"accession_number":"0001683168-25-007462","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health enters $100K promissory note with 18% interest, issues 100K-share warrant at $0.10","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note for $100,000 from Peter D'Arruda, due Sept. 30, 2026, with 18% annual interest.","Company issued a warrant to purchase 100,000 shares of common stock at $0.10 per share.","Warrant exercisable for five years from Oct. 1, 2025; contains 4.99% beneficial ownership limitation.","Proceeds provide working capital; borrower may prepay without penalty before maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139391,"accession_number":"0001683168-25-007178","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity of $1.05M convertible note to Jan 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Convertible promissory note dated April 5, 2021, principal $1,050,000.","Amendment No. 10 extends maturity date from prior date to January 31, 2026.","All other terms and conditions of the note remain unchanged.","Effective date of amendment is July 31, 2025; filed September 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139390,"accession_number":"0001683168-25-006584","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Odyssey Health closes $220K convertible note and warrant financing with Mast Hill Fund","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $220,000, one-year, 10% note convertible at 85% of 10-day VWAP; default rate 16%.","Warrant for 1M shares at $0.10, immediately exercisable, cashless exercise if market price exceeds $0.10.","Net proceeds ~$173,000 after $22,000 OID and $7,500 legal fee deduction.","Securities issued under Rule 506(b); no registration rights; acknowledges dilution to existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139389,"accession_number":"0001683168-25-006257","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends $300K promissory note maturity to Jan 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 1 extends maturity of $300,000 note from Aug 14, 2024 to Jan 31, 2026.","Lender is accredited investor Peter J. D'Arruda; all other terms unchanged.","Note originally entered Aug 14, 2024; extension executed Aug 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139388,"accession_number":"0001683168-25-006048","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends convertible note maturity to Jan 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 4 extends maturity of Feb 13, 2024 convertible note with Jonathan Lutz to January 31, 2026.","Effective date July 31, 2025; all other terms including interest and conversion remain unchanged.","Prior amendments 1-3 also remain in effect; no changes to principal amount or conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139387,"accession_number":"0001683168-25-005638","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Odyssey Health enters $25M equity purchase agreement with Mast Hill Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $25M equity purchase agreement with Mast Hill Fund; shares sold at 97% of VWAP discount.","Company may direct Mast Hill to purchase up to $500K or 20% of avg daily trading value per put.","Agreement runs 24 months; company can terminate anytime without penalty.","Proceeds for general corporate purposes, working capital, R&D, and officer compensation.","Mast Hill beneficial ownership capped at 4.99%; no short selling or hedging allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139386,"accession_number":"0001683168-25-005637","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity of promissory notes with officers/directors to Jan 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Four Promissory Note Amendments No. 11 extend maturity date from prior to January 31, 2026.","Notes originally issued Dec 2021, amended multiple times; lenders are two directors and two officers.","Each note principal is $25,000; all other terms remain unchanged.","Amendments effective July 31, 2025, filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139385,"accession_number":"0001683168-25-005057","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends promissory note maturity to Oct 10, 2025 with Mast Hill Fund","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date of $870,000 promissory note extended to October 10, 2025.","Amendment No. 5 with Mast Hill Fund, L.P.; all other terms unchanged.","Original note issued December 13, 2022; principal amount remains $870,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156970,"accession_number":"0001683168-25-004083","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FINRA approves Odyssey Health name change, effective May 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FINRA approved name change from Odyssey Group International to Odyssey Health on OTC Markets, effective May 27, 2025.","Symbol ODYY remains unchanged; no stock split or reverse split.","Shareholder approval occurred Sept 2021; Nevada Articles amendment effective Oct 2021.","Name change is purely cosmetic; no impact on operations, assets, or financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175344,"accession_number":"0001683168-25-001124","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity dates on two promissory notes to July 31, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended Jon Lutz promissory note maturity to July 31, 2025 (Amendment No. 3).","Extended $1.05M convertible note with LGH Investments maturity to July 31, 2025 (Amendment No. 9).","Filing states all other terms and conditions remain the same for both notes.","Both amendments executed in February 2025; LGH amendment effective December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175343,"accession_number":"0001683168-25-000784","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity of insider promissory notes to July 31, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Four promissory notes held by two directors and two officers amended for tenth time.","Maturity date of each note extended from previous date to July 31, 2025.","All other terms and conditions of the notes remain unchanged.","Notes originally dated December 2021, with nine prior amendments since April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208776,"accession_number":"0001683168-24-006007","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health receives $300,000 via 18% promissory note; issues warrant for 300k shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $300,000 from accredited investor Peter J. D'Arruda on August 22, 2024, per promissory note dated August 14, 2024.","Note bears 18% annual interest, matures August 14, 2025; company may prepay at any time.","Issued warrant to purchase 300,000 shares of common stock at $0.10 per share, exercisable for five years.","Warrant contains 4.99% beneficial ownership limitation; shares unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245519,"accession_number":"0001683168-24-000097","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends convertible note maturity to June 30, 2024, adds $60K principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended convertible promissory note with LGH Investments; maturity extended to June 30, 2024.","$60,000 added to principal outstanding as consideration for the extension.","New conversion price set at $0.12 per common share.","Company may prepay at 110% of balance after a 30-day holder conversion option.","Original note dated April 5, 2021, for $1,050,000; other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262998,"accession_number":"0001683168-23-009136","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.","Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.","Closing conditions included shareholder approvals from both Odyssey and Oragenics; no material adverse change required.","Odyssey previously disclosed the Purchase Agreement in an October 5, 2023 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262997,"accession_number":"0001683168-23-008821","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Odyssey Health shareholders approve asset sale to Oragenics for $1M cash + 8M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders voted 45,032,700 for, 382,191 against the asset sale to Oragenics.","$1M total cash consideration: $500k paid on signing, second $500k paid after shareholder approval on Dec 11.","Upon closing, Odyssey will receive 8M shares of Oragenics Convertible Preferred Class F stock (1:1 conversion to common).","Transaction expected to close before end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262996,"accession_number":"0001683168-23-008697","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Odyssey Health shareholders approve asset sale of neurological drug therapies to Oragenics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Approved asset purchase agreement of neurological drug therapies and technologies to Oragenics, Inc.","Vote: 45,032,700 for, 333,249 against, 48,943 abstaining on the asset purchase agreement.","Approved adjournment proposal: 44,826,263 for, 255,690 against, 332,939 abstaining.","Special meeting held on December 7, 2023; results filed via 8-K Item 5.07."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262995,"accession_number":"0001683168-23-007598","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends maturity of officer/director promissory notes to Jan 31, 2024; conversion at $0.12/share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $25,000 promissory notes from two officers and two directors to January 31, 2024.","Conversion price remains at $0.12 per share; notes convertible prior to maturity.","All other terms of the original December 2021 notes unchanged.","This is the seventh amendment to the notes, previously amended multiple times in 2022 and 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262994,"accession_number":"0001683168-23-006996","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Gandolfo resigns from Odyssey Health board effective October 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Gandolfo resigned as director on October 5, 2023.","Resignation was not due to any disagreement with the company.","No other board or officer changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262993,"accession_number":"0001683168-23-006962","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.","Transaction expected to close Q4 2023, subject to shareholder approvals and other conditions, including Oragenics having ≥$5M cash at close.","ONP-002 completed Phase 1 trial; Phase 2 preparation underway; animal studies show reduced swelling, inflammation, oxidative stress.","Odyssey management members intend to join Oragenics post-close to continue development.","Odyssey retains other assets and operations; Oragenics expands into neurological therapeutics via intranasal delivery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280182,"accession_number":"0001683168-23-005902","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health issues $500K convertible note with warrants tied to Spinco IPO","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note purchase agreement with two accredited investors for $500,000 principal amount.","Note due 12 months from execution or upon completion of a Senior Exchange Listing of Spinco.","12% annual interest; convertible into Spinco common stock at 70% of Spinco's IPO price.","Warrants permit purchase of 200% of loan amount divided by Spinco IPO price.","Proceeds to fund uplist pursuit, legal, and general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280181,"accession_number":"0001683168-23-004719","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends notes from directors/officers and LGH to late 2023; conversion price set at $0.12","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity on five promissory notes from directors/officers to Oct 31, 2023; conversion price $0.12/share.","Extended $1,050,000 LGH convertible note maturity to Dec 31, 2023; $25,000 added to principal.","LGH note interest set at 8% per annum; conversion price fixed at $0.12 per share.","All other terms and conditions of the notes remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298715,"accession_number":"0001683168-23-004486","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.","Transaction makes Speranza a wholly owned subsidiary of Odyssey; Speranza management to remain post-closing.","Merger subject to due diligence, financing, and other conditions; deal terms were not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298714,"accession_number":"0001683168-23-002142","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends convertible note maturity to June 30, 2023; adds $20K principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $1.05M convertible note held by LGH Investments to June 30, 2023; $20K added to principal.","Extended five promissory notes totaling $125K with three directors and two officers to same maturity date.","The notes were originally issued December 2021 and have been amended multiple times prior.","All other terms and conditions of the notes remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318910,"accession_number":"0001683168-23-000189","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Odyssey Health shareholders approve reverse stock split; Conroy resigns from board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock approved: 39.8M for, 4.4M against, 39k abstain.","All director nominees elected except Jeffrey Conroy, who resigned on Jan 4, 2023.","Advisory vote on executive compensation passed: 34.6M for, 3.4M against, 466k abstain.","Turner Stone & Company ratified as auditor for FY ending July 31, 2023: 44.0M for, 58k against.","Vote took place at Jan 12, 2023 Annual Meeting; results filed on Jan 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318909,"accession_number":"0001683168-23-000100","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeffrey Conroy resigns from Odyssey Health board effective Jan 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Conroy resigned as director effective January 4, 2023.","Resignation not due to any disagreement with the company.","No replacement named or further details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318908,"accession_number":"0001683168-23-000003","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends convertible note maturities to March 31, 2023; adds $50K principal to one note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 4 with LGH extends $1.05M note maturity to March 31, 2023; adds $50K to principal, paydown $35K.","Amendments with three directors and two officers extend their promissory notes to March 31, 2023.","Amendment with investor Jonathan Lutz extends note maturity to January 31, 2023.","All other terms and conditions remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337143,"accession_number":"0001683168-22-008034","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-11-25T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.","Raised over $5M in funding; access to Lincoln Park equity line of up to $10M.","Added two key executives with pharmaceutical drug development experience to management.","Filed patent application for novel breath-propelled intranasal delivery device.","Developed nanoparticle spray-dried formulation in partnership with UK partner under GMP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337142,"accession_number":"0001683168-22-008028","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Odyssey Health receives $313,709 R&D rebate from Australian government for Phase I trial work","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rebate of $313,709 ($468,727 AUD) received on November 18, 2022.","Funds are for clinical work conducted in Australia during fiscal year ended July 31, 2022.","Rebate relates to the Company's Phase I human clinical trial expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337141,"accession_number":"0001683168-22-008027","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health acquires option to purchase PRV-001 patents from Prevacus for 1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Option to buy 100% of worldwide patents to PRV-001 and an Enantiomer from Prevacus.","Consideration for option: 1,000,000 shares of Odyssey common stock.","If exercised, asset purchase price: 2M shares for PRV-001, 1M shares for Enantiomer.","Option exercisable within 180 days of Nov 22, 2022; closing within 90 days after exercise.","Odyssey will also enter an asset purchase agreement upon exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337140,"accession_number":"0001683168-22-007279","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Odyssey Health hires CCO and COO for NeuroPharma; salaries contingent on $5M fundraising","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Emerson named CCO and Greg Gironda named COO of Odyssey NeuroPharma, effective Nov 1, 2022.","Each receives one-year term at 33% part-time commitment; base salary of $125K payable only after company raises $5M.","Each granted 600K stock options: 125K vest on signing, 300K upon $5M+ financing, 175K upon Nasdaq/NYSE listing.","Executives bring over 50 years combined pharmaceutical commercialization experience.","Odyssey aims to advance concussion and Niemann-Pick treatments through Phase II trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337139,"accession_number":"0001683168-22-007168","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health files patent for intranasal brain-drug device; Phase I study successful","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).","Phase I study of PRV-002 concussion drug via Nasal Device completed; well-tolerated in 40 healthy volunteers.","No Nasal Device failures documented; device deposits drug deep into nasal cavity for direct CNS diffusion.","CEO Michael Redmond cited advantage of direct brain delivery with fewer side effects for neurological treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337138,"accession_number":"0001683168-22-006742","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey Health extends convertible note maturity to Dec 31, 2022; adds $115K principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment with LGH Investments extends $1.05M convertible note maturity to Dec 31, 2022; principal increased by $115,000.","Separate amendments with three directors and two officers extend five promissory notes ($25K each) to same Dec 31, 2022 maturity.","All other terms of the underlying notes remain unchanged.","Total incremental debt from the LGH amendment is $115,000; no new borrowing from officer/director notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337137,"accession_number":"0001683168-22-006716","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health dissolves sports advisory board, provides concussion drug update: Phase I complete, Phase II planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dissolved sports advisory board to eliminate distraction and maintain focus on drug development.","Phase I human trial completed; drug proven safe and well tolerated.","Company plans to initiate Phase II trial to evaluate efficacy and safety in concussed patients.","Company states it has never received government funding; drug development funded by accredited investors.","Intellectual property and rights to the drug purchased on March 1, 2021 from a third party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354513,"accession_number":"0001683168-22-006708","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.","Pharmacokinetic analysis showed linear dose-plasma relationship; intranasal route suggests greater brain delivery.","Company plans to proceed to Phase II trials, working with FDA and U.S. military for site identification and study design.","Concussion treatment global market valued at $6.9B (2020), forecast $8.9B by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354512,"accession_number":"0001683168-22-006428","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Odyssey Health receives 8M shares back from shareholder; shares retired to treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholder returned 8 million common stock shares to the company on September 15, 2022.","Shares received by transfer agent and placed in treasury; all rights and title relinquished.","Return reduces outstanding share count, potentially increasing EPS and ownership percentages for remaining holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354511,"accession_number":"0001683168-22-005897","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.","No severe adverse events; vital signs, EKG, and blood labs normal.","Pharmacokinetics showed linear dose-concentration relationship and no drug accumulation.","Safety Review Committee unanimously approved start of MAD Cohort II (higher dose).","Low blood levels suggest intranasal delivery may target brain directly with fewer side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354510,"accession_number":"0001683168-22-005196","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Odyssey Health receives 7.37M shares returned to treasury; total 23.18M shares returned since Dec 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholder returned 7,370,000 shares; received by transfer agent on July 27, 2022.","Shares returned to treasury; all rights, title, and interest relinquished.","Since December 2021, total 23,179,578 shares of common stock returned to treasury.","Reduction in outstanding shares may improve per-share metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354509,"accession_number":"0001683168-22-004911","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.","Cohort III (8 healthy volunteers) cleared; Safety Review Committee unanimously approved start of Multiple Ascending Dosing (MAD) Cohort I.","Intranasal delivery showed low blood levels of PRV-002, supporting targeted brain delivery hypothesis.","Company planning FDA meeting to present Phase I data; Phase II trial sites and study design under development.","Global concussion treatment market valued at $6.9B (2020), forecast to reach $8.9B by 2027 (Grandview Research)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372492,"accession_number":"0001683168-22-003281","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health reports positive initial Phase I results for concussion drug PRV-002","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.","Phase I trial ongoing with 48 healthy subjects in single and multi-ascending dose components.","Company plans to present Phase I data to FDA, then initiate Phase II trial in US starting with military.","Concussion affects over 3 million annually in US; no FDA-approved treatment currently exists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372491,"accession_number":"0001683168-22-003279","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Odyssey Health closes second closing of private placement; gross proceeds $415,650","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing issued 1,781,358 Units at $0.35/Unit for gross proceeds of $415,650.20.","Each Unit: one common share plus half-warrant (exercise $0.70, 5-year term, cashless exercise possible).","Net from second closing $374,085; total net from both closings $1,223,387.","Company must file resale registration statement within 60 days of final closing or pay liquidated damages.","Private placement on 'Minimum' basis; minimum gross $999,999.70, max $4,999,999.90."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372490,"accession_number":"0001683168-22-002838","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Odyssey Health adds Vice Admiral (r) Timothy Szymanski to Military Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vice Admiral (r) Szymanski served 36 years as Navy SEAL, most recently Deputy Commander USSOCOM.","He established cognitive baseline policy for Special Operations and created brain health initiatives.","Odyssey's concussion drug candidate PRV-002 is currently in Phase 1 clinical trial.","Up to 3.8 million concussions occur annually in the U.S., with 30-50% unreported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372489,"accession_number":"0001683168-22-002837","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Odyssey Health closes initial $1.0M private placement of 4.3M units at $0.35","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First closing on April 14, 2022, issued 4,306,200 units at $0.35 each; each unit equals one share and one-half warrant.","Gross proceeds of $1,004,780; net proceeds of $849,302 after offering expenses.","Investor warrants have 5-year term, exercise price of $0.70 per share, eligible for cashless exercise.","Private placement has minimum of $999,999.70 and maximum of $4,999,999.90; remaining closings possible.","Company must file resale registration statement within 60 days of final closing or pay liquidated damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372488,"accession_number":"0001683168-22-002667","cik":1626644,"company_name":"Odyssey Health, Inc.","ticker":"ODYY","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Odyssey extends convertible note maturity to March 2023, principal increased by $25K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $250K convertible note to March 1, 2023; added $25K to principal balance.","Holder Tysadco Partners LLC granted conversion moratorium until maturity unless default occurs.","Effective date March 31, 2022; filing reported April 11, 2022.","Odyssey Health Inc. (ODYY) entered amendment with Tysadco Partners LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1867265.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-14T23:59:59+00:00|372488"}